Evidence map›Paper›PMID 42022779›Full record

ArticleACS catalysis2026

Generative Artificial Intelligence-Empowered Virtual Evolution of Enzyme with the VERnet Model.

Chang Li, Wenfeng Xu, Hang Yang, Yifei Li, Lili Zhang, Ziwei Chen, Shuanghu Wang, Yibo Xie, Hexin Li, Ye Liu and 7 more

Abstract read
In one paragraph

Article in ACS catalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chang LiDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, P.R. China.ORCID https://orcid.org/0000-0001-9588-8118
Wenfeng XuDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, P.R. China.
Hang YangDepartment of Basic Innovation Research, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Beijing Key Laboratory of Aging Mechanism and Intervention Research on Aging-Related Diseases, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, P.R. China.
Yifei LiClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Lili ZhangClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Ziwei ChenClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Shuanghu WangLaboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui 323000, China.
Yibo XieInformation Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Hexin LiClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Ye LiuClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.ORCID https://orcid.org/0000-0001-5827-5240
Yayu LiClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Zebei LuLaboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui 323000, China.
Chunqing ZhangNational Institutes for Food and Drug Control, Beijing 102629, China.
Xue YuDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.
Dapeng DaiDepartment of Basic Innovation Research, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Beijing Key Laboratory of Aging Mechanism and Intervention Research on Aging-Related Diseases, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, P.R. China.ORCID https://orcid.org/0000-0002-6279-7102
Pengfei JinDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, P.R. China.
Fei XiaoClinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.ORCID https://orcid.org/0000-0003-2054-901X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large language models (LLMs) have demonstrated their limitations in addressing the design of active proteins that rely on intricate intramolecular interactions, particularly in the engineering of biocatalysts. Conducting real-world studies from targeted laboratory assays has become the de facto standard for artificial intelligence (AI) research in complex biological tasks. In this study, we present a standardized strategy using function-targeted models to decode the subtle effect of sequence variations on the function. Unlike affinity-oriented protein-protein interaction studies using LLMs, our model targets the specific functional interpretation, thereby guiding enzyme evolution. We established the VERnet model using deep mutation scanning data that underwent self-distillation, achieving an optimal accuracy of 93.5% for interpreting CYP2C9 variants. Through directed evolution at conserved positions enhanced by generative AI, we identified multiple CYP2C9 variants exhibiting a broad range of functional alterations. Additionally, a fine-tuned model optimized by AlphaFold3 significantly improved the prediction of variants involving the substitution of two amino acids. Molecular dynamics simulations revealed the structural and dynamic features of the catalytic alterations in evolved variants. The

Indexed as

catalytic activityCYP2C9enzyme evolutionmachine learningprotein structurevariant effect prediction

Identifiers

PMID42022779
PMCPMC13097142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.